Answers are grounded in this paper and cite their sources.
Mouse overexpression data warrant no clinical change; leaves open human translation of angiopoietin-1 for therapeutic angiogenesis.
The angiopoietins and members of the vascular endothelial growth factor (VEGF) family are the only growth factors thought to be largely specific for vascular endothelial cells. Targeted gene inactivation studies in mice have shown that VEGF is necessary for the early stages of vascular development and that angiopoietin-1 is required for the later stages of vascular remodeling. Here it is shown that transgenic overexpression of angiopoietin-1 in the skin of mice produces larger, more numerous, and more highly branched vessels. These results raise the possibility that angiopoietins can be used, alone or in combination with VEGF, to promote therapeutic angiogenesis.
No takes yet. Share an insight, caveat, or question.
Suri et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: